Women on Ozempic‑Like Drugs Saw Lower Breast Cancer Rates – What It Means for GLP‑1 Investors

A large Penn Medicine analysis found that women taking GLP‑1 drugs such as Ozempic and Wegovy from Novo Nordisk (NYSE: NVO), and Mounjaro or Zepbound from Eli Lilly (NYSE: LLY), were about 30–35% less likely to be diagnosed with breast cancer than similar women who did not use these medicines. Researchers looked at health data from more than 110,000 women aged 45 to 80 and adjusted for factors like age, BMI, race, breast density and diabetes status, so the signal appears consistent across different patient profiles.

However, the absolute difference in risk was still under 1 percentage point, and this was an observational study, so it cannot prove that GLP‑1 drugs directly prevent breast cancer. Many other factors — including weight loss itself, healthier behaviors and closer medical follow‑up — may contribute to the lower cancer rates seen in GLP‑1 users.

Investor lens on NVO, LLY and VKTX

For investors, the study adds another data point to the idea that GLP‑1 drugs may deliver broad metabolic‑health benefits, not just weight loss and glucose control. That narrative supports long‑term enthusiasm for leaders like Novo Nordisk (NVO) and Eli Lilly (LLY), which already dominate the obesity‑drug market, and for pipeline players such as Viking Therapeutics (NASDAQ: VKTX), which is developing its own next‑generation weight‑loss therapies.

If future randomized trials confirm that GLP‑1‑based drugs can safely lower cancer or cardiovascular risk, the total addressable market for obesity treatments could expand even further, reinforcing the premium valuations that NVO and LLY already command and potentially lifting sentiment around emerging names like VKTX. At the same time, regulators will require much stronger evidence before approving any explicit cancer‑prevention claims, so in the near term this study mainly supports the “metabolic‑health halo” around the GLP‑1 class rather than changing product labels.

What this means for investors

For the investment story, the key watch items are still durability of demand, pricing power, competition within the GLP‑1 class, and how convincingly companies like NVO, LLY and VKTX can show long‑term health outcome benefits beyond weight loss. If those broader outcomes continue to trend positive, today’s study is one more brick in a larger wall supporting the long‑run obesity‑drug theme.